Search

Heron Therapeutics Inc

Suletud

SektorTervishoid

0.32 -3.03

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.33

Max

0.35

Põhinäitajad

By Trading Economics

Sissetulek

2.6M

-5.5M

Müük

3M

38M

Aktsiakasum

-0.03

Kasumimarginaal

-14.573

Töötajad

128

EBITDA

2.1M

-5.5M

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-32M

65M

Eelmine avamishind

3.35

Eelmine sulgemishind

0.32

Uudiste sentiment

By Acuity

19%

81%

26 / 339 Pingereas Healthcare

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. sept 2026, 23:51 UTC

News

Toll Brothers Inc. shares are lower in after-market trading, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

9. sept 2026, 23:51 UTC

News

Lakeland Industries reported a fiscal Q2 net loss of $4.9 million and lower-than-expected sales, leading shares to decline in after-market trading.

9. sept 2026, 23:51 UTC

News

Limoneira Co reported third-quarter results that missed expectations, with revenues falling to $43.8 million and shares trading lower in after-market hours.

9. sept 2026, 23:51 UTC

Social Media
News

Lockheed Martin received $1.08 billion in defense contract modifications from the U.S. Department of Defense, boosting shares modestly higher during after-market hours.

9. sept 2026, 23:41 UTC

News

Ovintiv Inc shares are higher in after-market hours following Stifel's Buy rating and $92.00 price target from analyst David Deckelbaum.

9. sept 2026, 23:41 UTC

News

Chewy Inc shares fell in after-market trading following analyst downgrades and price target cuts from Jefferies and Evercore. The stock has declined for five consecutive sessions.

9. sept 2026, 23:41 UTC

News

America's CAR-MART Inc shares are lower in after-market hours following disappointing Q2 results, with revenue down 57.1% and a non-GAAP loss of $6.65 per share.

9. sept 2026, 23:36 UTC

News

DICK'S Sporting Goods is facing a class action lawsuit over alleged false statements regarding its business operations, contributing to a decline in after-market hours.

9. sept 2026, 23:31 UTC

Social Media
News

Apple Inc. introduced new AirPods 5 and Apple Watch Series 12, enhancing audio and health features. Shares are trading higher in after-market hours.

9. sept 2026, 23:26 UTC

News

Abbott Laboratories received U.S. FDA approval for its TactiFlex Duo ablation catheter. Shares are higher in after-market trading, reflecting a recovery from recent declines.

9. sept 2026, 23:21 UTC

News

L3Harris Technologies shares are trading higher in after-market hours, recovering from three consecutive declines despite broader market pressures from rising U.S. Treasury yields.

9. sept 2026, 23:21 UTC

News

Verizon shares are higher in after-market hours following a positive investor conference, where executives highlighted strong broadband growth and strategic cost-cutting measures.

9. sept 2026, 23:16 UTC

News

Joby Aviation appoints Sergey Novikov as Principal Accounting Officer, effective September 2026. Shares are higher in after-market trading following this leadership change.

9. sept 2026, 23:16 UTC

News

Dycom Industries shares are higher in after-market trading ahead of a meeting with KeyBanc on September 16, reflecting investor interest in strategic discussions.

9. sept 2026, 23:11 UTC

News

Nasdaq Inc shares advanced modestly in after-market trading following three consecutive lower sessions, amid rising crude oil prices and inflation concerns impacting monetary policy.

9. sept 2026, 23:06 UTC

News
Correlated Moves

Intuit Inc. filed an automatic mixed securities shelf, with shares trading lower in after-market hours, reflecting a broader decline and correlation with Adobe Inc.

9. sept 2026, 23:06 UTC

News

Boeing Co advances in U.S. Army interceptor competition, shares trading higher in after-market hours. Only two firms have progressed in the selection process.

9. sept 2026, 23:06 UTC

Social Media
News

Coca-Cola's CEO outlines a strategy focusing on digital advancements and balanced growth. Shares remain roughly flat in after-market trading since Wednesday's close.

9. sept 2026, 23:06 UTC

News

Stifel analyst David Deckelbaum resumed coverage on APA Corp with a Buy rating. Shares are higher in after-market hours, closing at $43.55.

9. sept 2026, 23:06 UTC

News

Conagra Brands Inc. shares rose in after-market trading after Slim Jim set a Guinness World Record for the longest meat snack stick at 429 feet.

9. sept 2026, 23:06 UTC

News

Simon Property Group priced $800 million in senior notes to repay debt. Shares are trading higher in after-market hours following the announcement.

9. sept 2026, 23:06 UTC

News
Correlated Moves

ADP data shows an increase of 12,000 jobs, influencing USD/CZK, which is trading higher. The pair remains within its one-month trading range.

9. sept 2026, 23:06 UTC

News

Permian Resources shares rise in after-market hours following a Buy rating from Stifel analyst David Deckelbaum and a target price of $30.00.

9. sept 2026, 23:06 UTC

Social Media
News

Meta Platforms Inc shares are lower in after-market hours following the departure of key AI researcher Andrew Tulloch and concerns over tax breaks for data centers.

9. sept 2026, 23:06 UTC

News

Beam Therapeutics shares are trading higher in after-market hours following a presentation at Citigroup's Biopharma Summit, highlighting advancements in its pipeline.

9. sept 2026, 23:02 UTC

Social Media
News

American Eagle Outfitters shares fell in after-hours trading following a second-quarter earnings report that included a $134.08 million net income and a cautious sales outlook.

9. sept 2026, 23:01 UTC

Event
Social Media
News

Cooper Companies reported a net income of $432.8 million but missed revenue expectations, leading to a decline in after-hours trading. Fourth-quarter guidance was lowered.

9. sept 2026, 23:01 UTC

News

Wix.com Ltd shares decline in after-market hours amid legal challenges from two class action lawsuits over misleading statements about its AI offerings and costs.

9. sept 2026, 23:01 UTC

News

T-Mobile US participated in Citi's TMT Conference, where CFO Peter Osvaldik announced his retirement. Shares are higher in after-market trading.

9. sept 2026, 23:01 UTC

Social Media
News

Adobe shares declined in after-market hours amid concerns over OpenAI's advertising policy affecting its product promotion. The stock remains below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Neutraalne

2 ratings

0

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

26 / 339 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat